Early Magnesium Sulfate for Children With Moderate Asthma Attacks
Tests magnesium sulfate given early in children having moderate asthma attacks.
Plain-language title generated from the registry record
Registry title: Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
Key facts
- Where
- Oklahoma City, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 17 years old?
Source: NCT06137040, who can take part
Where in United States
- Oklahoma Children's HospitalOklahoma City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Oklahoma
- Trial code
- NCT06137040
- Record updated
- 6 December 2024
- Original description
This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.Read full original descriptionShow less
Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.
Inclusion: Ages 5-17 years old; Presents to the ED with a respiratory score in the "Moderate" range (6; Parent(s)/Caregiver(s) speak English.
Exclusion: Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients; Patients who are pregnant; Parent(s)/Caregiver(s) do not speak English.